Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 692-701

  Kaye, S B ^a   Mead, G M ^b   Fossa, S ^b   Cullen, M ^b   DeWit, R ^b   Bodrogi, I ^b   Van Groeningen, C ^b   Sylvester, R ^b   Collette, L ^b   Stenning, S ^b   De Prijck, L ^b   Lallemand, E ^b   DeMulder, P ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; GERM CELL TUMOR; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0031943997     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.692     Document Type: Article

References (27)

1. Einhorn L: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1877-1881, 1990
2. Paz-Ares L, Kaye SB: Schedule intensive treatment for testicular germ cell tumours, in Jones W, Harnden P, Appleyard I (eds): Germ Cell Tumors III. Oxford, United Kingdom, Pergamon, 1994, pp 261-270
3. Mead GM, Stenning SP, Parkinson MC, et al: The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 10:85-94, 1992
4. Lewis CR, Fossa SD, Mead G, et al: BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumors. Ann Oncol 2:203-211, 1991
5. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
6. Yusuf S, Peto R, Lewis J, et al: Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovas Dis 27:335-371, 1985
7. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1691-1692, 1988
8. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Ass 53:457-481, 1958
9. Nichols CR, Loehrer PJ, Einhorn LH, et al: Phase III study of cisplatin, etoposide and bleomycin (BEP) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumors; An Intergroup trial. Proc Am Soc Clin Oncol 14:239, 1995 (abstr)
10. International Germ Cell Cancer Collaborative Group: The International Germ Cell Consensus Classification - A prognostic factor based staging sytem for metastatic germ cell tumors. J Clin Oncol 15:594-603, 1997
11. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
12. Nichols CR, Anderson J, Lazarus HM, et al: High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol. J Clin Oncol 10:558-563, 1992
13. Motzer RJ, Mazundar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
14. Chevreau C, Droz JP, Pico JL, et al: Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French national trial. Eur J Urol 23:213-218, 1993
15. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
16. Bosl GJ, Geller NL, Vogelzang NJ, et al: Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol 5:436-440, 1988
17. Logothetis CJ, Samuels ML, Selig DE, et al: Cyclic chemothrapy with cyclophosphamide, doxorubicin and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med 81:219-228, 1986
18. Amato R, Finn L, Sella A, et al: Lack of survival benefit for peak dose intensity in patients with non-seminomatous germ cell tumor of the testis treatment with CISCA II/VB IV chemotherapy: Results of a randomized trial. Proc Soc Am Clin Oncol 12:233, 1993 (abstr)
19. Stoter G, Kaye S, Sleyfer D, et al: Preliminary results of BEP (bleomycin, etoposide, cisplatin) versus an alternating regimen of BEP and PVB (cisplatin, vinblastine, bleomycin) in high volume metastatic testicular non-seminomas. An EORTC study. Proc Am Soc Clin Oncol 5:106, 1986 (abstr)
20. Hitchins, RN, Newlands ES, Smith DB, et al: Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: Comparison of commonly used classification systems of good and poor prognosis. Br J Cancer 59:236-242, 1989
21. Cullen MH, Harper PG, Woodroffe CM, et al: Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime. Br J Urol 62:454-460, 1988
22. Husband DJ, Green JA: POMB/ACE chemotherapy in nonseminomatous germ cell tumours: Outcome and importance of dose intensity. Eur J Cancer 28:86-91, 1992
23. Harstrick A, Schmoll HJ, Kohne-Wompner CH, et al: Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol 2:197-202, 1991
24. Germa Lluch JR, Segui Palmer MA, Climent Duran MA, et al: Intensive chemotherapy in poor-prognosis non-seminomatous germ cell tumours of the testis. Eur J Urol 21:287-293, 1992
25. Wettlaufer JN, Feiner AS and Robinson WA: Vincristine, cisplatin and bleomycin with surgery in the management of advanced metastatic non-seminomatous testis tumors. Cancer 53:203-209, 1994
26. Dearnaley DP: Intensive induction treatment of poor risk patients, in Horwich A (ed): Testicular Cancer: Investigation and Management. New York, NY, Chapman & Hall, 1991, pp 233-248
27. Horwich A, Wilson C, Dearnaley DP: Rapidly cycled chemotherapy for poor prognosis metastatic non-seminomatous germ cell cancer. Br J Cancer 66:39, 1992 (suppl 17)